Translational Research in Oncology
Translational Research in Oncology (TRIO), headquartered in California, is a pioneering organisation dedicated to advancing cancer research and treatment. Founded in 2010, TRIO has established itself as a leader in the oncology sector, focusing on the integration of clinical and laboratory research to enhance patient outcomes. With a strong presence in North America and Europe, TRIO is committed to developing innovative clinical trials and collaborative research initiatives. Their unique approach combines cutting-edge methodologies with a patient-centric focus, ensuring that new therapies are both effective and accessible. Notable achievements include successful partnerships with leading academic institutions and pharmaceutical companies, positioning TRIO at the forefront of translational oncology. By bridging the gap between research and clinical application, TRIO continues to make significant strides in the fight against cancer.
DitchCarbon Score
How does Translational Research in Oncology's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Translational Research in Oncology's score of 3 is lower than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Translational Research in Oncology's reported carbon emissions
Translational Research in Oncology, headquartered in California, currently does not have available emissions data for the most recent year, nor do they have specified reduction targets or climate pledges. Without specific figures or commitments, it is unclear how the organisation is addressing carbon emissions or contributing to climate action within the oncology research sector. As the industry increasingly prioritises sustainability, it is essential for organisations like Translational Research in Oncology to establish clear climate commitments and reduction strategies to align with global efforts in mitigating climate change.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Translational Research in Oncology is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
